Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal [Yahoo! Finance]
Palvella Therapeutics, Inc. (PVLA)
Company Research
Source: Yahoo! Finance
the exercise of 4,302 options and immediately sold an equivalent number of common shares on March 18, 2026, according to an SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value ~$508,000 Transaction value based on SEC Form 4 weighted average purchase price ($117.99). Key questions How was this transaction structured, and what does it signal about insider liquidity? This event comprised the exercise of 4,302 stock options into common stock, with the entire amount immediately sold in the open market, a pattern consistent with liquidity-motivated and tax-driven transactions commonly found in Rule 10b5-1 trading plans. What was the impact on Goin's direct ownership in Palvella Therapeutics, Inc? The sale reduced Goin's direct common stock holdings to zero, as reported in the Form 4; however, she retains exposure through directly owned stock options. How does the transaction's scale and cadence compare to prior activity? The
Show less
Read more
Impact Snapshot
Event Time:
PVLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVLA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVLA alerts
High impacting Palvella Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PVLA
News
- Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual MeetingGlobeNewswire
- Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win [Yahoo! Finance]Yahoo! Finance
- Palvella Therapeutics (PVLA) had its price target raised by HC Wainwright from $255.00 to $270.00. They now have a "buy" rating on the stock.MarketBeat
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026 [TheStreet.com]TheStreet.com
- Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026GlobeNewswire
PVLA
Earnings
- 11/11/25 - Miss
PVLA
Sec Filings
- 3/20/26 - Form 4
- 3/18/26 - Form 144
- 3/2/26 - Form 4
- PVLA's page on the SEC website